Guggenheim raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $86 from $84 and keeps a Buy rating on the shares following the company’s Q4 earnings last week, a follow-up conversation with management, and the firm’s analysis of mid-quarter prescription trends for Cortrophin and the company’s generics business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Reports Record 2024 Results and Raises 2025 Guidance
- Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific
- ANI Pharmaceuticals Reports Record Growth and Raises 2025 Outlook
- Morning Movers: Bloom Energy higher following quarterly results
- ANI Pharmaceuticals Files Form 8-K with SEC